19 August 2026 (Wednesday) - NEQAS 2603DM

I finally got the result of 2603DM today…  “a 43-year-old man who regularly attends Haematology outpatients. The blood film was prepared after new features were noticed in his blood count. Your opinion is requested”.
 
I can’t remember it at all, but at the time I said: “I’d say he regularly attends haematology outpatients because of a haemoglobinopathy. There’s target cells, sickle cells, nucleated red cells, polychromasia and Howell-Jolly bodies there.
And there’s blast cells and smear cells.
And there’s  an eosinophilia too.
 
The platelet count is down as well
 
I’d say this is someone with sickle cell disease (possibly HbSC or with a co-existing thalassaemia because of the target cells) who has suddenly developed leukaemia”.
 
The expert opinion was “This is a case of sickle cell disease (HbSS) with typical red cell features including sickle cells, boat-shaped cells, hyposplenic features and nRBCs. However, in this case there are also blast cells which should not be present and indicate the additional presence of an acute leukaemia. The important principle here is to recognise that we like to consolidate all features of a diagnostic blood film into a single diagnosis (e.g. sickle cell anaemia with reactive/hyposplenic features, or an acute leukaemia or myelofibrosis with associated red cell change). The key is sometimes to focus on the really key findings – in this case the blast cells, thrombocytopenia and typical sickle cells. Then ask whether this is really compatible with a single disorder”.
 
So… I’d spotted all the salient features. I got it right. 

 

18 August 2026 (Tuesday) - QC on the TOP

 


Still sulking about the BTLP-TACT debacle I had a look at the Werfen academy.
I had a go at one of the courses – “ACL TOP Family 50 Series - Running QC”.
I passed. That cheered me up a bit…

18 August 2026 (Tuesday) - Getting the BTLP Wrong (Again)

I had a little time on my hands this morning so I did a BTLP-TACT exercise.
I was presented with two cases:
 
47778 – a ninety-nine year-old woman in out patients needing group and save prior to hip replacement surgery.
She grouped as AB Rh(D) Positive with a negative antibody screen.
 
36230 – a twenty-nine year-old woman in the maternity unit needing group and save prior to induction of labour.
She grouped as A Rh(D) Negative with antibody screen positive in all three cells. I performed antibody panels.
The enzyme panel was negative throughout.
The IAT panel was positive in cells 1, 2, 3, 5, 6, 7, 9 and 10 corresponding with anti-S and anti-Fy(a)
 
I got it wrong. Apparently anti-K could not be excluded. I’m not happy about this. In previous exercises I was told that a negative reaction in the enzyme panel *did* rule out anti-K in the simulator (I know it don't in real life).
 

17 August 2026 (Monday) - Sounds Like Sezary's Syndrome...

 The LEAST recommended diagnostic test is option 1. Bone marrow aspirate and biopsy

The patient shows the typical clinical picture of Sézary syndrome (cutaneous T-cell lymphoma, likely stage T4NxB2M0), characterized by erythroderma (erythema involving >80% of the body surface area), generalized lymphadenopathy and lymphocytosis with a TCR rearrangement shared between the skin and the blood. Skin biopsies, PET-CT and lymph node biopsies are indicated for diagnosis and staging. In the absence of unexplained cytopenia, a bone marrow study is generally not necessary. 
First-line therapies include low-dose methotrexate, extracorporeal photopheresis, retinoids and interferon. Mogamulizumab (an anti-CCR4 monoclonal antibody) is the treatment of choice for relapsed/refractory disease. Allogeneic transplantation should be considered in selected cases.

Reference: 
  • Dummer R, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7(1):61. Published 2021 Aug 26. 
  • Latzka J, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023. Eur J Cancer2023;195:113343. 
  • Olsen E, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722. 

16 August 2026 (Sunday) - I've Heard Of It...

 


Well, I’ve heard of Chediak-Higashi syndrome, but don’t think I’ve actually seen it in real life.. Here’s as good a place as any to start with it.

It’s not restricted to humans…


15 August 2026 (Saturday) - DOAC

I finally got round to signing up to the Werfen Academy today, and got full marks on my first course “Introduction to Direct Oral Anticoagulants (DOACs)”.
Go me…

 

14 August 2026 (Friday) - Seriously?

I’m not quite old enough to remember the first Moon landings, but I remember the Apollo 13 disaster and Skylab. I remember Dolly (the first cloned sheep) and Louise Brown (the first test-tube baby).
I had such high hopes for the future… it turned out to be such a disappointment.